ACADIA Pharmaceuticals is trading at $20.61, down 21.96%, with no clear company-specific catalyst identified for the September 22, 2026 after-hours decline.
- Recent available coverage highlights earlier second-quarter results and a preliminary derivative-lawsuit settlement; neither directly explains the move.
- The broader market was mixed, with the Nasdaq up 0.61%, so market sentiment does not clearly account for the drop.